These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22610034)

  • 21. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
    Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
    Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of nitroheterocycles active against African trypanosomes. In vitro screening and preliminary SAR studies.
    Arán VJ; Kaiser M; Dardonville C
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4506-16. PubMed ID: 22738640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
    Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
    Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.
    Jacquemard U; Dias N; Lansiaux A; Bailly C; Logé C; Robert JM; Lozach O; Meijer L; Mérour JY; Routier S
    Bioorg Med Chem; 2008 May; 16(9):4932-53. PubMed ID: 18439832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
    Wilson KJ; Illig CR; Chen J; Wall MJ; Ballentine SK; DesJarlais RL; Chen Y; Schubert C; Donatelli R; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3925-9. PubMed ID: 20570147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and proapoptotic properties of new casein kinase II inhibitors.
    Koronkiewicz M; Zukowska M; Chilmonczyk Z; Orzeszko A; Kazimierczuk Z
    Acta Pol Pharm; 2010; 67(6):635-41. PubMed ID: 21229880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.
    Gianoncelli A; Cozza G; Orzeszko A; Meggio F; Kazimierczuk Z; Pinna LA
    Bioorg Med Chem; 2009 Oct; 17(20):7281-9. PubMed ID: 19748274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of novel 2 (4`-hydroxynaphthyl) chromen-4-one as a CK2 inhibitor.
    Haidar S; Jabbour M; Al-Khayat MA; Aichele D; Jose J
    Pharmazie; 2018 Apr; 73(4):191-195. PubMed ID: 29609684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
    Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
    J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2.
    Syniugin AR; Ostrynska OV; Chekanov MO; Volynets GP; Starosyla SA; Bdzhola VG; Yarmoluk SM
    J Enzyme Inhib Med Chem; 2016; 31(sup4):160-169. PubMed ID: 27590574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
    Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities.
    Akhtar J; Khan AA; Ali Z; Haider R; Shahar Yar M
    Eur J Med Chem; 2017 Jan; 125():143-189. PubMed ID: 27662031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.
    Ostrynska OV; Balanda AO; Bdzhola VG; Golub AG; Kotey IM; Kukharenko OP; Gryshchenko AA; Briukhovetska NV; Yarmoluk SM
    Eur J Med Chem; 2016 Jun; 115():148-60. PubMed ID: 27017545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors.
    Martín-Acosta P; Haider S; Amesty Á; Aichele D; Jose J; Estévez-Braun A
    Eur J Med Chem; 2018 Jan; 144():410-423. PubMed ID: 29288942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a potent and selective chemical probe for the pleiotropic kinase CK2.
    Wells CI; Drewry DH; Pickett JE; Tjaden A; Krämer A; Müller S; Gyenis L; Menyhart D; Litchfield DW; Knapp S; Axtman AD
    Cell Chem Biol; 2021 Apr; 28(4):546-558.e10. PubMed ID: 33484635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
    Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
    Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.
    Cozza G; Bonvini P; Zorzi E; Poletto G; Pagano MA; Sarno S; Donella-Deana A; Zagotto G; Rosolen A; Pinna LA; Meggio F; Moro S
    J Med Chem; 2006 Apr; 49(8):2363-6. PubMed ID: 16610779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.